课题基金 / 基金详情

Exploration of Genome Stability as a Therapeutic Target in Cancer

Exploration of Genome Stability as a Therapeutic Target in Cancer
探索基因组稳定性作为癌症治疗靶点
批准号:
8639355
负责人:
Rahul Nene
金额:
$3.66万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2016-03-31

项目摘要

项目成果

Rahul Nene的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):在许多癌症中看到的基因组不稳定被认为产生了驱动肿瘤发生的突变(Hanahan和Weinberg 2000)。然而,导致这种不稳定性的缺陷可能是癌细胞的脆弱性。 化疗特别针对和杀死(D.A.Chan和Giaccia,2011年)。在存在缺陷导致比正常水平更高的DNA损伤时,细胞可能变得依赖于补偿途径,以减少DNA损伤的影响,防止细胞激活死亡途径。如果这些非必要的补偿机制现在在癌细胞中是必不可少的,那么使这些机制失活的治疗将以一种特定的基因型方式特异性地杀死癌细胞。这种靶向本质上是一种基于治疗的合成致死性形式,当两个基因单独失活时效果最小,但同时失活两个基因会导致细胞生长减少或细胞死亡。聚(ADP-核糖)聚合酶(PARP)抑制剂治疗BRCA1和BRCA2基因缺陷癌症的成功表明,在双链断裂(DSB)修复缺陷的背景下,合成致死性激发的方法可以成功(Bryant等人)。2005年;Farmer等人。2005)。PARP失活不太可能是BRCA1和BRCA2缺陷癌症靶向的唯一机制。然而,系统地筛选BRCA1和BRCA2缺陷的癌细胞存活所需的额外基因或途径既昂贵又具有技术挑战性,这是因为需要高通量实验,难以识别真正致命的条件, 以及被击倒的基因的不完全失活。在这里,我将利用与酿酒酵母中DSB修复途径突变的遗传相互作用来鉴定BRCA1和BRCA2缺失的癌细胞株生存所需的候选人类基因。鉴于真核DNA修复机制的高度保守性质(Aggarwal和Brosh 2012),我将使用先前确定的合成致命性相互作用以及新的 确定了导致基因组不稳定性增加和对DNA损伤剂的敏感性增加的相互作用,以识别感兴趣的酵母基因。然后,我将使用这些酵母基因的人类同源物的siRNA敲除来确定人类癌细胞系中是否存在同等的相互作用。最后,我将探索在人类癌细胞系中验证的这些相互作用是否可以用作诱导细胞死亡的靶点。我希望这些实验将提供一种合理的方法,为未来的治疗开发确定一组高度丰富的新靶点。
英文摘要
DESCRIPTION (provided by applicant): The genome instability seen in many cancers is thought to generate the mutations that drive tumorigenesis (Hanahan and Weinberg 2000). The defects that lead to this instability, however, may be a vulnerability by which cancer cells can be specifically targeted and killed by chemotherapies (D. A. Chan and Giaccia 2011). In the presence of defects causing higher than normal levels of DNA damage, cells may become reliant upon compensating pathways that reduce the impact of the DNA damage and prevent the cells from activating death pathways. If these non-essential compensating mechanisms are now essential in the cancer cells, then treatments inactivating these mechanisms would specifically kill cancer cells in a genotype-specific fashion. This targeting is essentially a therapy-based form of synthetic lethality, which is observed when inactivation of two genes individually has minimal effect, but simultaneous inactivation of both results in decreased cell growth or cell death. The success of poly(ADP-ribose) polymerase (PARP) inhibitors against cancers with defects in the BRCA1 and BRCA2 genes demonstrates that a synthetic lethality inspired approach can be successful in the context of defects in double-strand break (DSB) repair (Bryant et al. 2005; Farmer et al. 2005). Inactivation of PARP is unlikely to be the only mechanism by which BRCA1 and BRCA2 deficient cancers can be targeted. Systematic screening for additional genes or pathways that are required for BRCA1 and BRCA2 deficient cancer cell survival, however, is both expensive and technically challenging due to the requirements for a high-throughput experiment, difficulties in identifying truly lethal conditions, and incomplete inactivation of genes that are knocked down. Here, I will use genetic interactions with mutations in the DSB repair pathway in the yeast Saccharomyces cerevisiae to identify candidate human genes required for the survival of BRCA1 and BRCA2 deficient cancer cell lines. Given the highly conserved nature of the eukaryotic DNA repair mechanisms (Aggarwal and Brosh 2012), I will use previously identified synthetic lethality interactions as well as newly identified interactions giving rise to increased genome instability and increased sensitivity to DNA damaging agents to identify yeast genes of interest. I will then use siRNA knockdown of human homologs of these yeast genes to determine whether equivalent interactions exist in human cancer cell lines. Finally, I will explore if those interactions validated in human cancer cell lines can be used as a target to induce cell death. I expect these experiments will provide a rational approach to identify a highly enriched set of new targets for future therapeutic development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploration of Genome Stability as a Therapeutic Target in Cancer
海外基金